Bridging the Digital Divide: Real-World Efficacy of Commercial and Open-Source Automated Insulin Delivery Systems in a Diverse, Low-Resource Pediatric Population
Authors' conclusion
In a heterogeneous real-world pediatric cohort including a low-resource population with limited technological access, both AID systems significantly improved glycemic outcomes without compromising safety.
Study context
- Population
- Children with T1D treated at Shaare Zedek Medical Center, heterogeneous real-world cohort including low-resource population; Socioeconomic status (SES) by residential address
- Participants
- 61 children
- Exposure
- Open-source AndroidAPS automated insulin delivery (AID) vs regulatory-approved Medtronic 780G; AID vs prior sensor-augmented pump therapy
- AndroidAPSn = 31
- Medtronic 780Gn = 30reference
- Outcome
- Changes in TIR, average glucose, GMI and hypoglycemia/hyperglycemia duration (AID vs prior sensor-augmented pump therapy)
Methodological detailsreal-world, single-centre
- Real-world
- Single-centre
Main finding
As reported in the abstract
Glycemic outcomes, prior sensor-augmented pump vs AID (both groups)
%time in range (TIR), prior therapy vs AID (mean ± SD)
56.6 ± 14.1 vs 69.3 ± 8.8
Average blood glucose, prior therapy vs AID (mean ± SD)
173.3 ± 31.7 vs 149.9 ± 18.3
Observational data: associations, not effects.
Safety
Events
| Outcome | Medtronic 780G | AndroidAPS |
|---|---|---|
| Severe hypoglycemia and DKA | 0 | 0 |
Original publication
Bridging the Digital Divide: Real-World Efficacy of Commercial and Open-Source Automated Insulin Delivery Systems in a Diverse, Low-Resource Pediatric Population. J Diabetes Sci Technol. Published 25 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →